News for ACADIA Pharmaceuticals Inc. (0A4W.L)

The FDA Commissioner Marty Makary stated the FDA will reach its 2025 drug approval targets despite severe workforce reductions.

Acadia Pharmaceuticals (ACAD) has received a favorable ruling from the Federal Court of Appeals, which upholds the validity of its '740 composition of matter pa

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Court of Appeals for the Federal Circuit affirmed a decision issued by the U.S. Distri

Summary: Acadia Pharmaceuticals (ACAD) successfully upholds its key patent in a significant legal victory. Analysts predict a potential 21.08% upside, wi

In a recent analyst update, ACADIA Pharmaceuticals (ACAD) has received a significant price target boost from JP Morgan. The investment firm, represented by anal

JPMorgan has increased its price target for Acadia Pharmaceuticals (ACAD) from $26 to $30, maintaining an Overweight rating on the company's shares. This adjust

On June 4, 2025, Laura Brege, a Director at ACADIA Pharmaceuticals Inc (ACAD), sold 14,446 shares of the company, as reported in a SEC Filing. Following this tr

Summary ACADIA Pharmaceuticals Inc (ACAD) has announced its participation in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference, sche

Acadia Pharmaceuticals (ACAD) appoints Allyson McMillan-Youngblood as Senior Vice President of Rare Disease Franchise. Allyson brings over 20 years of e

In a recent development, ACADIA Pharmaceuticals, known by its stock ticker ACAD, has seen a significant upgrade from Deutsche Bank. The financial services firm

Acadia Pharmaceuticals (ACAD) has received an upgrade from Deutsche Bank, moving from a Hold to a Buy rating. The firm has raised the price target for ACAD to $

Deutsche Bank has elevated its rating for Acadia Pharmaceuticals (ACAD) to Buy from Hold, significantly increasing the price target to $35 from $20. This decisi

We recently published a list of 10 Surprising Stocks That Skyrocketed Today. In this article, we are going to take a look at where ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals (ACAD) received an updated price target from Mizuho analyst Uy Ear. The analyst has maintained a "Neutral" rating on the stock, but has r

On May 19, 2025, renowned analyst Joel Beatty from Baird released an update on ACADIA Pharmaceuticals (ACAD), emphasizing a promising outlook for the company's

ACADIA Pharmaceuticals (ACAD) has received significant attention from RBC Capital, as analyst Gregory Renza reiterates an "Outperform" rating on the stock. This

Acadia Pharmaceuticals (ACAD) recently secured a significant legal victory regarding its formulation patent for the drug Nuplazid, used in treating Parkinson's

Mizuho has increased its price target for Acadia Pharmaceuticals (ACAD) from $20 to $23, maintaining a Neutral rating on the stock. This adjustment follows a fa

ACADIA Pharmaceuticals Inc ACAD announced a favorable court ruling on Friday. The U.S. District Court for the District of Delaware upheld the validity and foun...